Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-008-0084-y
Annals of Surgical Oncology 15:2894-2902 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barbour, A. P.
Right arrow Articles by Smithers, B. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Barbour, A. P.
Right arrow Articles by Smithers, B. M.

Original Article

Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response

Andrew P. Barbour, MBBS, PhD1, Mark Jones, PhD2, Mithat Gonen, PhD3, David C. Gotley, MD1, Janine Thomas, BN1, Damien B. Thomson, MBBS4, Bryan Burmeister, MBBS5 and B. Mark Smithers, MBBS1

1 Department of Surgery, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Queensland 4102, Australia
2 Department of Biostatistics, Princess Alexandra Hospital, Brisbane, Queensland, Australia
3 Department of Epidemiology-Biostatistics, Memorial Sloan–Kettering Cancer Center, New York, NY, USA
4 Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
5 Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia

Correspondence: Address correspondence and reprint requests to: Andrew P. Barbour, MBBS, PhD; E-mail: a.barbour{at}uq.edu.au

Objective: Accurate staging is vital for esophageal cancer management. The utility of the American Joint Committee on Cancer (AJCC) staging system 6th edition for esophageal cancer has been questioned for resected patients who receive neoadjuvant chemoradiotherapy (CRT). This study was undertaken to assess the AJCC staging system for patients with esophageal cancer that have received neoadjuvant CRT and to identify clinicopathological variables that predict survival.

Methods: Review of a prospective esophageal cancer database was undertaken for patients that received neoadjuvant CRT and resection. Primary tumor response was defined as major (≤10% residual tumor cells) or minor (> 10% residual tumor cells). Cox regression and concordance analyses were used to determine prognostic factors. Median follow-up was 61 months.

Results: Of 131 patients with invasive cancer, there were 40/131 (31%) with squamous cell carcinoma (SCC) and 88/131 (65%) with adenocarcinoma. The procedure-related mortality rate was 3.8%. Median survival was 33 months. A major response was demonstrated by 79/131 (60%) patients. Survival analyses found that the AJCC 6th edition was unable to discriminate between stages 0, I, and IIa or stages IIb and III. Multivariate survival analyses found age, pretreatment tumor length > 6 cm, positive lymph nodes, and a major tumor response were independent prognostic factors. These data were used to derive a new staging system that had improved discrimination of stage groups over the current AJCC system.

Conclusion: The current AJCC staging system for esophageal cancer is inadequate for patients that receive neoadjuvant CRT. Refinement of the AJCC staging system should include primary tumor response for patients receiving neoadjuvant CRT.

Key Words: Esophageal cancer • Staging • Prognostic factors • Chemoradiotherapy






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.